+1.32%
Today
Loading 1D prices…
Company profile
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Sector
Health Care
Industry
Medicinal Chemicals & Botanical Products
Exchange
Nasdaq
Display currency
USD
Location
YAVNE, Israel, United States
Employees
121
Fiscal year end
1231
CIK
1593984
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc. Common Stock | $239.7M | $129.4M | +13.43% | $0.20 | +2.00% | Buy |
| ACBAurora Cannabis Inc. Common Shares | $261.2M | — | — | -$2.14 | -1.78% | Buy |
| USNAUSANA Health Sciences Inc. Common Stock | $264.9M | $925.3M | +1.16% | $0.58 | +1.57% | Sell |
| BONBon Natural Life Limited Class A Ordinary Shares | $310.8M | $18.7M | -10.68% | -$0.72 | +1.26% | Unrated |
| SNDLSNDL Inc. Common Shares | $344.6M | — | — | -$0.06 | -0.36% | Hold |